Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells

2001 • 1,384 citations

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1995 • 1,097 citations

Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines

1994 • 841 citations

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1998 • 586 citations

Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells.

1988 • 565 citations

HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation

1992 • 522 citations

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

1996 • 416 citations

Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation.

1990 • 227 citations

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

2001 • 223 citations

Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts

1997 • 209 citations

Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.

1997 • 161 citations

Delineation of several DR-restricted tetanus toxin T cell epitopes.

1989 • 136 citations

Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination.

1992 • 135 citations

Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development

1998 • 135 citations

Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma

2000 • 131 citations

Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 Alleles

1998 • 114 citations

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

2001 • 114 citations

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

1996 • 106 citations

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

1996 • 51 citations

Tumor antigens and tumor vaccines: Peptides as immunogens

1996 • 48 citations

Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides.

1994 • 42 citations

Low‐dose IL‐2 treatment: Activation of discrete T‐ and NK‐cell sub‐populations in vivo

1995 • 30 citations

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma

1996 • 13 citations

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.

1992 • 10 citations